



YEAR END 2022 FINANCIAL STATEMENTS AND MANAGEMENT NOTES

Dear Shareholder,

Please find the Company's Year End 2022 financial statements and management notes attached.

As 2022 came to a close, New View Surgical marked the transition to the commercial phase of our business, releasing the initial clinical production run of the VisionPort System and completing our initial in-human procedures with our novel minimally invasive access and visualization system. As we enter 2023, we're focused on executing on our limited market release, with the goal to collect robust clinical and economic data in support of our value proposition and learn from our partner surgeons as we refine our strategy for full commercial release in the second half of 2023.

Additionally, in Q4, with the sole support of our current investors, we oversubscribed our Series B-1 equity raise, closing on \$12.1M in additional funding. The Series B-1 round provides the Company with a projected 18-month runway plus \$2M contingency reserve under the current operating budget. Critical areas of investment include production of commercial inventory, collection of clinical and economic data, adding headcount in critical functions, creation of additional intellectual property and focused product development initiatives.

Consistent with our past financial reports, we have provided management's comments on the financial statements below to assist you in your review. As always, we appreciate your support and commitment to New View Surgical. Please do not hesitate to contact me should you have any questions.

Sincerely,

Bryce Klontz
President & CEO

[Click here to see our FY 2022 Financial Statements and Notes](#)